Tags

Type your tag names separated by a space and hit enter

Prescribing practices in a population-based HIV postexposure prophylaxis program.
AIDS. 2002 May 03; 16(7):1067-70.AIDS

Abstract

OBJECTIVES

To characterize factors associated with being prescribed triple or double postexposure prophylaxis (PEP) against HIV in a population-based program.

METHODS

Individuals potentially exposed to HIV received a 5 day starter kit of either double or triple antiretroviral PEP between April 1999 and November 2000 and did/did not receive the remaining 23 days PEP. Data were collected through dispensation of kits. Logistic regression identified characteristics independently associated with being prescribed triple therapy starter kits and with any 23 day follow-up.

RESULTS

Of 2064 people receiving 5 day PEP [403 (20%) triple and 1661 (80%) double], 590 (29%) received 23 day follow-up. Independently associated with being prescribed triple therapy starter kits were being male [adjusted odds ratio (AOR) 1.38; 95% confidence interval (CI) 1.10-1.74; P = 0.006), occupational mucocutaneous injuries (AOR 1.70; 95% CI, 1.14-2.55; P = 0.010), and community needlesticks (AOR 2.04; 95% CI, 1.54-2.69; P < 0.001). Independently associated with being prescribed the 23 day follow-up were being male (AOR 1.24; 95% CI, 1.00-1.53; P = 0.04), community mucocutaneous incidents (AOR 2.83; 95% CI, 1.41-5.70; P = 0.004), community needlesticks (AOR 1.75; 95% CI, 1.33-2.29; P < 0.001), and having received triple therapy as the starter kit (AOR 2.61; 95% CI, 2.07-3.29; P < 0.001).

CONCLUSIONS

Being prescribed triple therapy starter PEP was associated with being male and with experiencing an occupational mucocutaneous or community needlestick injury. Receiving the remaining 23 days PEP was associated with being male, experiencing a community mucocutaneous or needlestick injury, and triple therapy as the initial 5 day starter PEP.

Authors+Show Affiliations

Division of Epidemiology and Population Health, BC Centre for Excellence in HIV/AIDS, 608-1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11953474

Citation

Braitstein, Paula, et al. "Prescribing Practices in a Population-based HIV Postexposure Prophylaxis Program." AIDS (London, England), vol. 16, no. 7, 2002, pp. 1067-70.
Braitstein P, Chan K, Beardsell A, et al. Prescribing practices in a population-based HIV postexposure prophylaxis program. AIDS. 2002;16(7):1067-70.
Braitstein, P., Chan, K., Beardsell, A., McLeod, A., Montaner, J. S., O'Shaughnessy, M. V., & Hogg, R. S. (2002). Prescribing practices in a population-based HIV postexposure prophylaxis program. AIDS (London, England), 16(7), 1067-70.
Braitstein P, et al. Prescribing Practices in a Population-based HIV Postexposure Prophylaxis Program. AIDS. 2002 May 3;16(7):1067-70. PubMed PMID: 11953474.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prescribing practices in a population-based HIV postexposure prophylaxis program. AU - Braitstein,Paula, AU - Chan,Keith, AU - Beardsell,Ann, AU - McLeod,Alistair, AU - Montaner,Julio S G, AU - O'Shaughnessy,Michael V, AU - Hogg,Robert S, PY - 2002/4/16/pubmed PY - 2002/8/16/medline PY - 2002/4/16/entrez SP - 1067 EP - 70 JF - AIDS (London, England) JO - AIDS VL - 16 IS - 7 N2 - OBJECTIVES: To characterize factors associated with being prescribed triple or double postexposure prophylaxis (PEP) against HIV in a population-based program. METHODS: Individuals potentially exposed to HIV received a 5 day starter kit of either double or triple antiretroviral PEP between April 1999 and November 2000 and did/did not receive the remaining 23 days PEP. Data were collected through dispensation of kits. Logistic regression identified characteristics independently associated with being prescribed triple therapy starter kits and with any 23 day follow-up. RESULTS: Of 2064 people receiving 5 day PEP [403 (20%) triple and 1661 (80%) double], 590 (29%) received 23 day follow-up. Independently associated with being prescribed triple therapy starter kits were being male [adjusted odds ratio (AOR) 1.38; 95% confidence interval (CI) 1.10-1.74; P = 0.006), occupational mucocutaneous injuries (AOR 1.70; 95% CI, 1.14-2.55; P = 0.010), and community needlesticks (AOR 2.04; 95% CI, 1.54-2.69; P < 0.001). Independently associated with being prescribed the 23 day follow-up were being male (AOR 1.24; 95% CI, 1.00-1.53; P = 0.04), community mucocutaneous incidents (AOR 2.83; 95% CI, 1.41-5.70; P = 0.004), community needlesticks (AOR 1.75; 95% CI, 1.33-2.29; P < 0.001), and having received triple therapy as the starter kit (AOR 2.61; 95% CI, 2.07-3.29; P < 0.001). CONCLUSIONS: Being prescribed triple therapy starter PEP was associated with being male and with experiencing an occupational mucocutaneous or community needlestick injury. Receiving the remaining 23 days PEP was associated with being male, experiencing a community mucocutaneous or needlestick injury, and triple therapy as the initial 5 day starter PEP. SN - 0269-9370 UR - https://www.unboundmedicine.com/medline/citation/11953474/Prescribing_practices_in_a_population_based_HIV_postexposure_prophylaxis_program_ L2 - https://doi.org/10.1097/00002030-200205030-00014 DB - PRIME DP - Unbound Medicine ER -